1. Repository of OAI
Ελληνικά   English  
Saved Searches

Discover

Search


Current filters:

Clear current filters  or Add more filters

View Option


Results 11-20 of 37 (Search time: 0.005 seconds).

  The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment (Journal article)

  The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome (Journal article)

  The effects of orlistat on metabolic parameters and other cardiovascular risk factors (Journal article)

  The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia (Journal article)

  Plasma PAF-acetylhydrolase(Lp-PLA(2)) activity as a marker of small-dense LDL in subjects at median cardiovascular risk (Journal article)

  The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome (Journal article)

  The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia (Journal article)

  Effects of Fenofibrate and Orlistat, Alone or in Combination, on Plasma Visfatin Levels in Subjects with Metabolic Syndrome (Journal article)

  Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia (Journal article)

  Effects of orlistat and fenofibrate combination on LDL phenotype in overweight and obese patients with metabolic syndrome. The fenorli study (Journal article)